We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Subcutaneous Formulation

News List

BLA Submitted to FDA for Subcutaneous Formulation of DARZALEX® Utilizing ENHANZE® americanpharmaceuticalreview
July 16, 2019
Halozyme Therapeutics announced that its collaborator Janssen Biotech has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...
FDA Approves Subcutaneous Formulation of Actemra for use in Active Polyarticular Juvenile Idiopathic Arthritis drugs
May 17, 2018
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra® (tocilizumab)